Previous 10 | Next 10 |
Energy Focus (NASDAQ: EFOI ) -52% on Q4 earnings . More news on: Energy Focus, Inc., Evoke Pharma, Inc., Apyx Medical Corporation, Stocks on the move, Read more ...
AMES, Iowa, April 02, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced results from a Phase 2 study of NLG207, a nanoparticle formulation of the topoisomerase 1 inhibitor camptothecin, conducted in conjunction with The GOG Foundation, Inc. (GOG-3008), ...
Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The increasingly hot market for online video delivery is set to take another sharp ...
NewLink Genetics Corporation (NLNK) Q4 2018 Results Earnings Conference Call February 28, 2019, 04:30 PM ET Company Participants Lisa Miller - Director of Investor Relations Charles Link, Jr. - Co-founder, Chairman, Chief Executive Officer and Chief Scientific Officer Eugene Kenn...
AMES, Iowa, Feb. 27, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that a late-breaking abstract reporting results from a Phase 2 study of NLG207, a nanoparticle formulation of the topoisomerase 1 inhibitor, camptothecin, has been accepted for poste...
NewLink Genetics (NASDAQ: NLNK ): Q4 GAAP EPS of -$0.28 beats by $0.06 . More news on: NewLink Genetics Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...
AMES, Iowa, Feb. 27, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported consolidated financial results for the fourth quarter and year ended 2018, as well as progress in its clinical development programs. The Company also outlined key 2019 pr...
AMES, Iowa, Feb. 07, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its fourth quarter and full year 2018 financial results on Wednesday, February 27, 2019. The company has scheduled a conference call for 4:30 PM ET ...
NEW YORK, Feb. 01, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Marathon Oil Corporation (NYSE:MRO), Accuray Incorporated (NASDAQ:ARAY...
News, Short Squeeze, Breakout and More Instantly...
Kahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of NewLink Common Stock Kahn Swick & Foti, LLC Announces Summary Notice of Proposed Settlement Involving Purchasers of NewLink Common Stock PR Newswire NEW ORLEANS ...
AUSTIN, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced the appointment of Joseph S. McCracken, DVM, MS to the company's Board of Directors, effective March 23...
- Combined company, Lumos Pharma, Inc., to trade on Nasdaq under the stock symbol “LUMO” - Phase 2b trial expected to be initiated mid-2020 evaluating oral therapeutic candidate LUM-201 (ibutamoren) in Pediatric Growth Hormone Deficiency (PGHD) - Projected combined cash ...